SK Biopharmaceuticals-2022 earnings
SK Biopharmaceuticals shifts to red in 2022
SEOUL, Feb. 9 (Yonhap) -- SK Biopharmaceuticals Co. on Thursday reported its 2022 net loss of 139.4 billion won (US$110.5 million), swinging from a profit of 64.8 billion won a year earlier.
The company said in a regulatory filing that it posted an operating loss of 131.1 billion won for the year, compared with a profit of 95 billion won from the previous year. Annual revenue fell 41.2 percent to 246.2 billion won.
(END)
(C) Yonhap News Agency. All Rights Reserved
![[4K LIVE] TEMPEST(템페스트) 'nocturnal' Showcase Stage](/news/data/20251027/p179572206915679_655_h.jpg)
![[ENG/JPN/Full] TEMPEST(템페스트) 'In The Dark(어둠 속에서)' Showcase｜As I am｜한빈·형섭·혁·은찬·LEW·태래](/news/data/20251027/p179578205733686_156_h.jpg)
